Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revision
Previous revision
Last revisionBoth sides next revision
home:symptoms:skin [09.09.2012] – [Notes and comments] paulalberthome:symptoms:skin [08.23.2017] – [Immune response and skin disease] sallieq
Line 26: Line 26:
 ===== Immune response and skin disease ===== ===== Immune response and skin disease =====
  
-In human skin antimicrobial peptide (AMP) are produced mainly by keratinocytes, neutrophils, sebocytes or sweat glands and are either expressed constantly or after an inflammatory stimulus.(({{pubmed>long:18782030}})) As Schittek //et al.// explain, in several human skin diseasess, there is an inverse correlation between severity of the disease and the level of AMP production. Skin lesions of patients with atopic dermatitis show a diminished expression of the beta-defensins and the cathelicidin LL-37 (both of which are strongly expressed by the Vitamin D Receptor). Furthermore, these patients have a reduced amount of the AMP dermcidin in their sweat which correlates with an impaired innate defense of human skin //in vivo//. In addition, decreased levels of AMPs are associated with burns and chronic wounds. In contrast, overexpression of AMPs can lead to increased protection against skin infections as seen in patients with psoriasis and rosacea, inflammatory skin-diseases which rarely result in superinfection. In other skin diseases, e.g. in patients with acne vulgaris, increased levels of AMPs are often found in inflamed or infected skin areas indicating a role of these peptides in the protection from infection. These data indicate that AMPs have a therapeutical potential as topical anti-infectives in several skin diseases.(({{pubmed>long:18782030}}))+In human skin antimicrobial peptide (AMP) are produced mainly by keratinocytes, neutrophils, sebocytes or sweat glands and are either expressed constantly or after an inflammatory stimulus.(({{pubmed>long:18782030}})) As Schittek //et al.// explain, in several human skin diseases, there is an inverse correlation between severity of the disease and the level of AMP production. Skin lesions of patients with atopic dermatitis show a diminished expression of the beta-defensins and the cathelicidin LL-37 (both of which are strongly expressed by the Vitamin D Receptor). Furthermore, these patients have a reduced amount of the AMP dermcidin in their sweat which correlates with an impaired innate defense of human skin //in vivo//. In addition, decreased levels of AMPs are associated with burns and chronic wounds. In contrast, overexpression of AMPs can lead to increased protection against skin infections as seen in patients with psoriasis and rosacea, inflammatory skin-diseases which rarely result in superinfection. In other skin diseases, e.g. in patients with acne vulgaris, increased levels of AMPs are often found in inflamed or infected skin areas indicating a role of these peptides in the protection from infection. These data indicate that AMPs have a therapeutical potential as topical anti-infectives in several skin diseases.(({{pubmed>long:18782030}}))
  
  
Line 207: Line 207:
 All this has made me contact the skin and cancer foundation of Australia where I originally went and got my diagnosis of sarcoidosis 8 years ago. I spoke to them and told them about all this. It flew over there heads but they are willing to see me because my case was very interesting for them at the time and I think they want to know how all this stuff works because I'm the living proof of the MP working. All this has made me contact the skin and cancer foundation of Australia where I originally went and got my diagnosis of sarcoidosis 8 years ago. I spoke to them and told them about all this. It flew over there heads but they are willing to see me because my case was very interesting for them at the time and I think they want to know how all this stuff works because I'm the living proof of the MP working.
  
-//**Simon Elrahi**, MarshallProtocol.com//</blockquote>+//**Simonc**, MarshallProtocol.com//</blockquote>
  
  
home/symptoms/skin.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.